Ambrilia Biopharma likes to work with drug candidates when they're still in the early stages of development. Once they hit late stage, the company prefers to license them out for further development. The company is also working to manufacture better formulations of existing drugs to bring in cash. Ambrilia's pipeline includes anti-virals and a handful of oncology drug candidates including generic candidates Octreotide and Goserelin. While it is shifting its focus onto anti-viral drugs, the company is continuing with clinical trials of the two oncology drugs. Mid-shift, however, the company's funds dried up and it filed for bankruptcy protection in the Canadian courts.

Hyaluron, Inc. company specializes in aseptically filling syinges and vials with liquid and lyophilized (treated for preservation) products serving the medical and pharmaceutical markets. Hyaluron manufacturing facility can accomodate the needs of clients small and large, from pre-clincial batches to commercial scale development. Hyaluron's expertise also extends into scaling up formulations such as emulsions, viscous gels, suspensions, liposomes, and proteins which will eventually fill the vials and syringes of the company's clients. The company can fill about 150,000 syringes a day and 75,000 vials.

K-V Pharmaceutical Company (KV) is a fully integrated specialty pharmaceutical company that develops, manufactures, acquires and markets branded and generic/non-branded prescription pharmaceutical products. The Company has a range of dosage form capabilities, including tablets, capsules, creams, liquids and ointments. KV conducts its branded pharmaceutical operations through Ther-Rx Corporation (Ther-Rx) and its generic/non-branded pharmaceutical operations through ETHEX Corporation (ETHEX). Through Particle Dynamics, Inc. (PDI), the Company also develops, manufactures and markets value-added raw material products for the pharmaceutical, nutritional, personal care, food and other markets. The Company has developed a variety of drug delivery and formulation technologies, which are primarily focused in four principal areas: SITE RELEASE; tastemasking; oral controlled release, and oral quick dissolving tablets.

BioMS Medical Corp. was founded in 1998 and is headquartered in Edmonton, Canada. BioMS Medical Corp., a development stage biotechnology company, through its subsidiaries, engages in the development and commercialization of therapeutic technologies for the treatment of multiple sclerosis (MS) in Canada. Its lead product under development includes Dirucotide for the treatment of multiple sclerosis, which is being evaluated in two pivotal Phase III clinical trials for secondary progressive MS patients; and MAESTRO-01, a pivotal phase II/III trial in Canada and western Europe. The company also develops Maestro-02, an open-label follow-on study to the Maestro-01 pivotal phase II/III clinical trial of Dirucotide, which targets secondary progressive multiple sclerosis (SPMS), as well as MAESTRO-03 trial, a pivotal Phase III product to evaluate the safety and efficacy of Dirucotide in patients with SPMS in the United States. BioMS Medical Corp. has a licensing and development agreement with Eli Lilly and Company. The company was formerly known as EPS Capital Corp. and changed its name to BioMS Medical Corp. in July 2001.

Champions Biotechnology, Inc. company was founded in 1985 and is based in Baltimore, Maryland. Champions Biotechnology, Inc., a biotechnology company, engages in the development of advanced preclinical platforms and predictive tumor specific data to enhance the value of oncology drugs in the United States. Its preclinical platform is an approach based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting xenografts (Biomerk Tumorgrafts) in a manner that preserves the biological characteristics of the original human tumor. The company leverages its preclinical platform to evaluate and develop a portfolio of oncology drug candidates through preclinical trials; and plans to sell, partner or license such drug candidates to pharmaceutical and/or biotechnology companies.Champions Biotechnology provides Personalized Oncology Services to physicians in the field of oncology by establishing and administering expert medical information panels for their patients to analyze medical records and test results; to assist in understanding conventional and experimental options; and to identify and arrange for testing, analysis, and study of the patients cancer tissues. In addition, the company offers personalized Tumorgraft development and drug studies to physicians for evaluating the effects of cancer therapies on their patient's. It offers its platform and tumor specific data to other biotechnology and pharmaceutical companies. The company was formerly known as Champions Sports, Inc. and changed its name to Champions Biotechnology, Inc. in January 2007 as a result of change in its business focus towards biotechnology.

Warner Chilcott plc company was founded in 1968 and is headquartered in Rockaway, New Jersey. Warner Chilcott PLC, formerly Warner Chilcott Limited, is a Bermuda-based specialty pharmaceutical company focused on the women’s healthcare and dermatology segments of the United States pharmaceutical market. It is an integrated company with internal resources dedicated to the development, manufacturing and promotion of its products. Its operations are carried through its wholly-owned subsidiaries in the United States, Puerto Rico, the Republic of Ireland and Northern Ireland. The Companies franchises are comprised of complementary portfolios of established branded and development-stage products. In October 2009, the Company announced it completed the acquisition of The Procter & Gamble Company’s global branded prescription pharmaceutical business.

Bionovo, Inc. company was founded in 2002 and is based in Emeryville, California. Bionovo, Inc. is a clinical stage drug discovery and development company focusing on women’s health and cancer. The Company designs drugs derived from botanical sources, which have mechanisms of action. The Company’s drug candidate, Menerba, represents a class of receptor sub-type selective estrogen receptor modulator (SERM) for the treatment of vasomotor symptoms of menopause, or hot flashes. The Company has designed Menerba to selectively modulate estrogen receptor beta (ERβ). In preclinical studies, Menerba inhibited tumor growth, as well as bone resorption known to cause osteoporosis, which is developed during menopause. The Company was developing BZL101, an oral anti-cancer agent for advanced breast cancer during the year ended December 31, 2008. BZL101 is designed to take advantage of the metabolism of cancer cells. BZL101 inhibits glycolysis, a metabolic pathway on which cancer cells rely.

Santarus was founded in 1996 and is based in San Diego, California. Santarus, Inc., a specialty pharmaceutical company, engages in acquiring, developing, and commercializing proprietary products that treat upper gastrointestinal diseases and disorders. Its products include Zegerid capsules and powder for oral suspension, which are proprietary immediate-release formulations that combine antacids and omeprazole (a proton pump inhibitor) to treat upper gastrointestinal diseases and disorders, including gastroesophageal reflux disease (GERD); and Glumetza for the treatment of type 2 diabetes. The company is also developing a Zegerid tablet formulation, Budesonide MMX for the treatment of mild or moderate active ulcerative colitis, and Rifamycin SV MMX for the treatment of traveler’s diarrhea. It has strategic alliances with Schering-Plough to develop, manufacture, and sell Zegerid brand OTC products in the lower dosage strength of 20 mg of omeprazole in the United States and Canada; GlaxoSmithKline to develop, manufacture, and commercialize prescription and OTC products in approximately 100 countries, including in Africa, Asia, the Middle-East, and Central and South America; and Cosmo Technologies, Ltd, which grants Santarus exclusive rights to develop and commercialize Budesonide MMX and Rifamycin SV MMX for the United States market. The company sells its products to wholesale distributors in the pharmaceutical industry.

Genzyme Diagnostics was founded in 1981. A division of Genzyme, it develops, manufactures, and distributes "in vitro" diagnostic products, including point-of-care tests. The division also produces the raw materials (such as enzymes and antibodies used in tests for diabetes, cholesterol, and pancreatitis) and chemical reagents used by other diagnostic test manufacturers to make their own diagnostic tests. The company's point-of-care products (tests administered at a patient's bedside) include tests for strep A, mononucleosis, and bacterial vaginitis; it also offers several different pregnancy tests.

Healthpoint, Ltd. company was founded in 1992 and is based in Fort Worth, Texas. Healthpoint, Ltd. operates as a subsidiary of DFB Pharmaceuticals, Inc. Healthpoint, Ltd., a specialty pharmaceutical company, develops and markets pharmaceutical and medical products for the treatment of chronic wounds. It focuses on the prevention and treatment of diseased and traumatized skin and related soft tissue. The company provides tissue management products, which includes sterile enzymatic debriding ointment, extracellular matrix-based wound product, bacteriostatic dressing, ointment for perineal wounds, papain-urea debriding ointment, doxepin hydrocloride cream, moisturizing dermal wound cleanser, hydrogel wound dressing, odor eliminator, powder for superficial skin infections caused by yeast, and protectant for intact and injured skin, as well as healing, debriding, and deodorizing ointment. It also offers surgical products, such as brush-free scrubbing products, surgical scrubs, waterless scrubs, healthcare personnel handwash and rub, hand and body antiseptic, one-step prep solutions, and topical anesthetic sprays. The company serves healthcare market, which includes nurses, physicians, surgeons, nursing homes, home health agencies, and office-based practices. It distributes its products through drug wholesalers and medical/surgical distributors.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.